Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in nephrology and hypertension
UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
What's new in nephrology and hypertension
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Nov 2016. | This topic last updated: Dec 01, 2016.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.

ACUTE AND CHRONIC KIDNEY DISEASE

Thrombotic microangiopathy from interferon (October 2016)

Drug-induced thrombotic microangiopathy (DITMA) has been described with a number of chemotherapeutic, immunosuppressive, and other drugs. Unlike thrombotic thrombocytopenic purpura (TTP), DITMA is not associated with severely reduced ADAMTS13 activity, and the principal treatment is drug discontinuation rather than plasma exchange. A new report has provided strong evidence for interferon as a cause of TMA [1]. Patients receiving interferon who develop signs of a TMA should have the drug discontinued promptly before organ failure develops. (See "Drug-induced thrombotic microangiopathy", section on 'Immunosuppressive agents'.)

Migalastat and Fabry disease (August 2016)

The treatment of patients with Fabry disease primarily focuses upon replacing the missing or deficient enzyme (alpha-galactosidase A). Enzyme replacement therapy (ERT) is limited by infusion reactions and the development of antibodies against the drug. Migalastat hydrochloride is an oral pharmacologic chaperone that binds to and stabilizes specific mutant forms of alpha-galactosidase and is a potential alternative therapy. In a double-blinded trial, 67 patients with Fabry disease who were not on ERT were randomly assigned to treatment with migalastat or placebo for six months, followed by open-label migalastat for up to an additional 18 months [2]. Although enrolled patients were required to have mutant forms of alpha-galactosidase that were suitable for migalastat, only 50 of the 67 patients ultimately were confirmed to have amenable mutations. At six months, there was no difference in the primary endpoint, defined as the percent of patients with a ≥50 percent reduction in the number of Gb3 inclusions per kidney interstitial capillary. However, in a secondary analysis of the 50 patients confirmed to have migalastat-suitable mutations, there was a greater reduction in the mean number of Gb3 inclusions per kidney interstitial capillary in patients treated with migalastat compared with placebo. Further studies evaluating long-term outcomes in patients with amenable mutations are still needed. Migalastat has been approved for use in Europe but not in the United States. (See "Treatment of Fabry disease", section on 'Alternatives to ERT'.)

Plant-based low protein diet in chronic kidney disease (July 2016)

A randomized trial compared a very low protein, plant-based diet supplemented with ketoanalogues (KD) with a mixed source (plant- and animal-based) low-protein diet (LPD) among patients with a stable estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 [3]. At 18 months of follow-up, compared with the LPD group, fewer patients in the KD group reached the composite endpoint of >50 percent reduction in eGFR or initiation of renal replacement therapy (RRT) (42 versus 13 percent, respectively). Compared with the LPD group, fewer patients in the KD group required RRT (30 versus 11 percent).

Caution is warranted in interpreting these results, however. While there were no differences between groups in nutritional parameters, other studies have shown increased mortality among patients treated with a keto acid- and amino acid-supplemented very low protein diet. Concerns have also been raised about delayed registration of the trial in the public trials registry until after enrollment of some participants. (See "Dietary recommendations for patients with nondialysis CKD", section on 'Source of protein intake'.)

Early initiation of renal replacement therapy (June 2016)

It is unclear if the early initiation of renal replacement therapy (RRT) (ie, without an obvious indication such as severe hyperkalemia, metabolic acidosis, pulmonary edema or advanced uremic symptoms) provides any benefit to critically ill patients with acute kidney injury (AKI) compared with later initiations of RRT. Two new randomized trials have evaluated this in somewhat different patient populations. In the larger trial, 620 critically ill patients with severe AKI were randomized to early or delayed RRT [4]. There was no difference in 60-day mortality, and nearly one-half of patients in the delayed RRT group recovered without requiring RRT. In contrast, a second trial of 231 critically ill patients with more moderate AKI showed reduced 90-day mortality with earlier RRT [5]. In the delayed initiation group, only 11 patients ended up not requiring RRT, and early RRT reduced the duration of AKI and length of stay. However, we have lower confidence in the results of the smaller trial, because it is possible that the relatively small size of the trial resulted in an overestimate of the treatment benefit. It is otherwise difficult to understand how minor differences in the protocols and patient populations could achieve such dramatically different outcomes. Until further data are available, UpToDate suggests that RRT not be initiated in the absence of obvious clinical indications. (See "Renal replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Timing of elective initiation'.)

DIALYSIS

Regional anesthesia for hemodialysis arteriovenous fistula creation (November 2016)

Regional anesthesia during the creation of hemodialysis arteriovenous fistulas causes arterial and venous dilation, which may improve early fistula patency. In a trial that randomly assigned 126 adults receiving primarily radiocephalic or brachiocephalic fistulas to brachial plexus block or local anesthesia, brachial plexus block resulted in a higher rate of primary fistula patency and a trend toward a higher rate of functional patency at three months [6]. Based upon these findings, we suggest brachial plexus block for the creation of arteriovenous fistulas, rather than using local anesthesia alone. (See "Creating an arteriovenous fistula for hemodialysis", section on 'Type of anesthesia'.)

Predialysis education and choice of modality (November 2016)

Predialysis education regarding different dialysis modalities may increase the number of patients who opt for peritoneal dialysis. In a systematic review and meta-analysis, structured educational interventions were associated with a twofold increase in the odds of choosing peritoneal dialysis compared with standard care [7]. (See "Dialysis modality and patient outcome", section on 'Selection of dialysis modality'.)

GLOMERULAR DISEASE AND VASCULITIS

Durability of remission in idiopathic membranous nephropathy (November 2016)

Among patients with idiopathic membranous nephropathy (MN), the durability of remission (spontaneous or treatment-associated) is associated with improved renal survival. In a prospective study of 376 patients with idiopathic MN who achieved complete or partial remission of nephrotic-range proteinuria, persistent remission at 3, 6, 12, and 24 months, compared with disease relapse at those time points, was associated with a lower risk of the primary endpoint (end-stage renal disease or 50 percent reduction in estimated glomerular filtration rate) [8]. (See "Treatment of idiopathic membranous nephropathy", section on 'Prognosis'.)

Accuracy of the spot urine protein to creatinine ratio in patients with kidney disease (October 2016)

A spot urine protein to creatinine ratio (UPCR) is frequently used to estimate 24-hour proteinuria and to follow the effects of treatment in patients with proteinuric kidney diseases. However, a longitudinal study of patients with biopsy-proven glomerular disease [9] and a systematic review of studies of patients with lupus nephritis [10] have demonstrated that a spot UPCR may not accurately predict the result of a 24-hour urine, particularly in patients with lower degrees (<1 g/day) of proteinuria. These findings support our recommendation that a 24-hour urine collection should be the method of choice for initial quantification of proteinuria and for verification of changes in proteinuria before therapy is altered in patients with kidney disease. (See "Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on 'Accuracy of spot urine estimates'.)

B7-1 blockade does not improve posttransplant nephrotic syndrome in patients with recurrent FSGS (August 2016)

Primary idiopathic focal segmental glomerulosclerosis (FSGS) frequently recurs after kidney transplantation and the optimal treatment is unknown. An initial report demonstrated that the protein B7-1 is more highly expressed within kidneys of patients with recurrent FSGS and could serve as a therapeutic target. However, in a series of nine patients with recurrent idiopathic FSGS following transplantation, treatment with a B7-1 inhibitor (abatacept or belatacept) did not induce remission of proteinuria [11]. Among all nine patients, expression of B7-1 within podocytes was undetectable in kidney biopsies performed at the time of disease recurrence. B7-1 expression in podocytes was similarly absent from the biopsies of 22 additional patients with recurrent FSGS. Thus, in contrast with the prior study, B7-1 was not expressed during FSGS recurrence and B7-1 blockade was not effective in the treatment of recurrent idiopathic FSGS. (See "Focal segmental glomerulosclerosis in the transplanted kidney", section on 'Abatacept'.)

Rituximab in primary membranous nephropathy (July 2016)

Rituximab may have benefit among patients with idiopathic membranous nephropathy with a moderate risk of progression. In one unblinded trial, 75 patients with persistent proteinuria greater than 3.5 g/day after six months of treatment with angiotensin inhibition, diuretics, and a statin (nonimmunosuppressive therapy) were randomly assigned to rituximab or no rituximab [12]. Nonimmunosuppressive therapy was continued in all patients. At six months, there was no significant difference in the primary composite endpoint of complete or partial remission of proteinuria between patients. However, in a post-trial observational phase that followed patients for an additional 12 months, the rate of complete or partial remission was higher among patients treated with rituximab (65 versus 34 percent). In addition, patients treated with rituximab had less proteinuria and higher serum albumin levels. The role of rituximab for patients with primary membranous nephropathy is uncertain and further data are awaited. (See "Treatment of idiopathic membranous nephropathy", section on 'Rituximab'.)

HYPERTENSION

Outcomes in severe asymptomatic hypertension (hypertensive urgency) (November 2016)

There is no proven benefit from rapid reduction of blood pressure in patients with severe asymptomatic hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg). In one retrospective study of over 59,000 patients who presented in the ambulatory setting with severe asymptomatic hypertension, there was no difference in major adverse cardiovascular events, or prevalence of uncontrolled hypertension six months later, for patients sent to the emergency department or sent home from the office for outpatient blood pressure management [13]. Hospitalization rates were higher for those sent to the emergency department. This cohort study suggests that most patients with asymptomatic hypertensive urgency who present in the ambulatory setting can be managed as outpatients. (See "Management of severe asymptomatic hypertension (hypertensive urgencies) in adults", section on 'Rapidity of blood pressure lowering'.)

Angioplasty in renal artery stenosis (November 2016)

In patients with atherosclerotic renal artery stenosis, a meta-analysis of trials comparing percutaneous transluminal renal angioplasty (PTRA) with stent placement plus medical therapy with medical therapy alone found no benefit from PTRA on mortality, end-stage renal disease, major cardiovascular events, or blood pressure control [14]. One or more major periprocedural complications occurred in 7.1 percent of patients who underwent PTRA. Thus, in patients with renal artery stenosis and clinical characteristics similar to those enrolled in these trials, we suggest not revascularizing and instead treating with medical therapy alone. (See "Treatment of unilateral atherosclerotic renal artery stenosis", section on 'Revascularization versus medical therapy alone'.)

J-shaped relationship between blood pressure and cardiovascular outcomes (November 2016)

There may be a blood pressure threshold below which tissue perfusion is reduced and risk is increased for cardiovascular and renal events and mortality (a J-shaped curve between blood pressure and event rate). In a large international prospective observational study of patients with stable coronary artery disease and treated hypertension, achieved diastolic pressures below 70 and above 80 mmHg were independently associated with increased risk for adverse outcomes (figure 1) [15]. Similarly, achieved systolic pressures below 120 and above 140 mmHg were independently associated with increased risk for adverse outcomes (figure 2). However, these data are observational, and other evidence disputes the importance of these J-shaped curves, particularly for systolic pressure. Based upon the available evidence and the physiology of coronary perfusion, we generally try to avoid lowering the diastolic blood pressure to a value of <60 mmHg in most patients. (See "What is goal blood pressure in the treatment of hypertension?", section on 'J-shaped diastolic curve'.)

Intensive blood pressure control and long-term outcomes in CKD (August 2016)

Several trials have compared more versus less intensive blood pressure control in patients with chronic kidney disease (CKD); however, follow-up during these trials was four years or less. A meta-analysis that combined patient-level information on long-term follow-up from the two largest of these trials (AASK and MDRD, with 14 to 19 years of follow-up) found that more intensive blood pressure control during the trial was associated with reduced overall mortality (hazard ratio 0.87) [16]. The reduction in death was similar in patients with and without proteinuria. Aggressive blood pressure lowering also reduced the progression to ESRD, but the benefit was confined to those with proteinuric CKD. (See "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Meta-analyses'.)

Goal blood pressure in older adults (June 2016)

Goal blood pressure in older adults was examined in the Systolic Pressure Intervention Trial (SPRINT) [17]. SPRINT enrolled a subgroup of more than 2600 ambulatory adults aged 75 years or older, including 349 categorized as being fit, 1456 as less fit, and 815 as frail according to a validated frailty index. At 3.1 years, rates of both the primary cardiovascular endpoint and all-cause mortality were significantly lower among those assigned more intensive (goal <120 mmHg) versus less intensive (goal <140 mmHg) systolic blood pressure lowering. The benefit from more intensive blood pressure control was present in both fit and frail older adults. Serious adverse events were similar in the two treatment groups, and did not depend upon frailty. (See "Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension", section on 'Goal blood pressure'.)

NEPHROLITHIASIS

Dietary protein and the risk of kidney stones (November 2016)

Different types of dietary protein may have different effects on the risk of kidney stones. Earlier studies have found an association between high animal protein intake and an increased incidence of stone disease, at least in men, while vegetable protein intake has not been associated with stone risk. A new study suggests that the risk of stones may vary depending upon whether the source of the animal protein is dairy or nondairy [18]. Higher nondairy animal protein intake was associated with a trend toward an increase in stone risk, whereas higher dairy protein intake in young women was associated with a lower risk of stone disease. (See "Risk factors for calcium stones in adults", section on 'Protein'.)

PEDIATRIC NEPHROLOGY

Acute kidney injury in critically ill children (November 2016)

Children cared for in intensive care units (ICUs) are at increased risk of acute kidney injury (AKI). In a large prospective multicenter study of patients 3 months to 25 years of age cared for in over 30 pediatric ICUs worldwide, approximately 27 percent developed AKI and 12 percent developed severe AKI (stage 2 or 3 AKI) (table 1) [19]. Severe AKI was independently associated with an increased risk of death, and increasing severity was associated with increasing risk of death. These data reinforce the need to identify patients at risk for AKI or with mild AKI so that interventions to prevent further injury can be implemented. (See "Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis", section on 'Critically ill children'.)

TRANSPLANTATION

Screening for cardiovascular disease before kidney transplantation (October 2016)

Cardiovascular disease is the leading cause of mortality in kidney transplant recipients. Although pretransplant cardiac evaluation is recommended for potential transplant candidates, the optimal screening strategy has not yet been identified. In a prospective study comparing clinical risk factor assessment with coronary artery calcium (CAC) scores among 138 pretransplant patients, CAC scores were not superior to risk factor assessment in identifying patients who would benefit from noninvasive testing for coronary heart disease (CHD) [20]. Both clinical risk factor assessment and CAC scores had a poor positive predictive value but a high negative predictive value for identifying patients with CHD. (See "Evaluation of the potential renal transplant recipient", section on 'Coronary heart disease'.)

Pretransplant kidney biopsies in liver transplant candidates with renal dysfunction (September 2016)

Among liver transplant candidates with renal dysfunction, a pretransplant kidney biopsy can help to identify patients who should be considered for simultaneous liver-kidney transplantation (SLK). A small retrospective study found that when pretransplant kidney biopsy criteria (>40 percent glomerulosclerosis and/or >30 percent interstitial fibrosis) were used to select SLK candidates, allocation of a kidney could be avoided in 70 percent of liver transplant candidates with renal dysfunction [21]. Post-transplant glomerular filtration rates were similar over the first year for SLK and liver alone transplant patients; further studies and longer-term follow-up are indicated. (See "Renal function and nonrenal solid organ transplantation", section on 'Approach in liver transplant candidates'.)

Biopsy gene expression profiling in kidney transplant recipients to predict risk of chronic injury (September 2016)

Gene expression analysis may provide a new method of identifying kidney transplant recipients who are at risk of developing chronic allograft nephropathy. In a prospective study of 101 renal transplant recipients, a microarray analysis performed on three-month posttransplant renal allograft biopsies identified a set of 13 genes that independently predicted the development of histologic injury at 12 months and risk of renal allograft loss at two and three years post-biopsy [22]. Although further studies are needed, this gene set represents a promising approach that could be used to identify patients who may benefit from therapeutic strategies to prevent the progression to fibrosis. (See "Chronic renal allograft nephropathy", section on 'Future directions'.)

Perioperative complications in minimally invasive live donor nephrectomy (September 2016)

Minimally invasive donor nephrectomies account for more than half of live donor nephrectomies performed for kidney transplantation. A systematic review of over 32,000 minimally invasive live donor nephrectomies demonstrated a low operative mortality rate of 0.01 percent and low rates of intraoperative and postoperative complications (primarily bleeding and infections) [23]. Comparison of the different minimally invasive techniques found similar complication rates between hand-assisted versus non-hand-assisted, laparoscopic versus retroperitoneoscopic, and multiport versus single-port procedures. (See "Benefits and complications of minimally invasive live-donor nephrectomy", section on 'Donor morbidity'.)

Calcineurin inhibitor-sparing strategies following kidney transplantation (July 2016)

A number of different immunosuppressive approaches have been evaluated to reduce the risk of developing chronic allograft nephropathy related to calcineurin inhibitor therapy after kidney transplantation. A systematic review and meta-analysis of 88 randomized controlled trials involving renal transplant recipients evaluated the outcomes of four strategies (minimization, conversion, withdrawal, and avoidance) to limit exposure to calcineurin inhibitors among renal transplant recipients [24]. Minimization of the calcineurin inhibitor dose, when combined with mycophenolate mofetil, resulted in better renal function, a lower risk of biopsy-proven acute rejection, and a lower rate of graft loss compared with standard calcineurin inhibitor doses. In general, conversion (primarily to a mammalian target of rapamycin inhibitor) and avoidance strategies did not provide benefit, whereas withdrawal strategies increased the risk of acute rejection. Thus, consideration should be given to calcineurin inhibitor therapy minimization to help prevent the development and progression of chronic renal allograft nephropathy. (See "Chronic renal allograft nephropathy", section on 'Reducing calcineurin inhibitor exposure'.)

OTHER NEPHROLOGY

Microvascular outcomes with empagliflozin in patients with type 2 diabetes (July 2016)

There are few trials evaluating microvascular outcomes in patients taking sodium-glucose co-transporter 2 (SGLT2) inhibitors. Microvascular disease was a prespecified secondary outcome in a recent trial designed specifically to evaluate cardiovascular morbidity and mortality in patients with type 2 diabetes and established cardiovascular disease (CVD) [25]. In this trial, 7028 patients with type 2 diabetes and established CVD were randomly assigned to empagliflozin or placebo once daily; the majority of patients were also taking metformin, antihypertensives, and lipid-lowering agents. Incident or worsening nephropathy occurred in 12.7 and 18.8 percent of patients in the empagliflozin and placebo groups, respectively. The reduction in nephropathy drove the improved composite microvascular endpoint (the initiation of retinal photocoagulation, vitreous hemorrhage, diabetes-related blindness, or incident or worsening nephropathy) for empagliflozin. The mechanism behind the reduction in incident or worsening nephropathy with empagliflozin is likely multifactorial, but is thought to be largely related to a direct renovascular effect of empagliflozin. Whether other SGLT2 inhibitors have similar renal effects is unknown. There have been reports of acute kidney injury, some requiring hospitalization and dialysis, in patients taking canagliflozin or dapagliflozin. (See "Management of persistent hyperglycemia in type 2 diabetes mellitus".)

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Kavanagh D, McGlasson S, Jury A, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016.
  2. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 2016; 375:545.
  3. Garneata L, Stancu A, Dragomir D, et al. Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. J Am Soc Nephrol 2016; 27:2164.
  4. Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med 2016; 375:122.
  5. Zarbock A, Kellum JA, Schmidt C, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA 2016; 315:2190.
  6. Aitken E, Jackson A, Kearns R, et al. Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial. Lancet 2016; 388:1067.
  7. Devoe DJ, Wong B, James MT, et al. Patient Education and Peritoneal Dialysis Modality Selection: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68:422.
  8. Cattran DC, Kim ED, Reich H, et al. Membranous Nephropathy: Quantifying Remission Duration on Outcome. J Am Soc Nephrol 2016.
  9. Hogan MC, Reich HN, Nelson PJ, et al. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int 2016; 90:1080.
  10. Medina-Rosas J, Yap KS, Anderson M, et al. Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2016; 68:1310.
  11. Delville M, Baye E, Durrbach A, et al. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. J Am Soc Nephrol 2016; 27:2520.
  12. Dahan K, Debiec H, Plaisier E, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol 2016.
  13. Patel KK, Young L, Howell EH, et al. Characteristics and Outcomes of Patients Presenting With Hypertensive Urgency in the Office Setting. JAMA Intern Med 2016; 176:981.
  14. Raman G, Adam GP, Halladay CW, et al. Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: An Updated Systematic Review. Ann Intern Med 2016; 165:635.
  15. Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016.
  16. Ku E, Gassman J, Appel LJ, et al. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol 2016.
  17. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA 2016; 315:2673.
  18. Ferraro PM, Mandel EI, Curhan GC, et al. Dietary Protein and Potassium, Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones. Clin J Am Soc Nephrol 2016.
  19. Kaddourah A, Basu, RK, et al. Epidemiology of Acute Kidney Injury in Critically Ill Children and Young Adults. N Engl J Med 2016.
  20. Winther S, Bøttcher M, Jørgensen HS, et al. Coronary Calcium Score May Replace Cardiovascular Risk Factors as Primary Risk Stratification Tool Before Kidney Transplantation. Transplantation 2016; 100:2177.
  21. Pichler RH, Huskey J, Kowalewska J, et al. Kidney Biopsies May Help Predict Renal Function After Liver Transplantation. Transplantation 2016; 100:2122.
  22. O'Connell PJ, Zhang W, Menon MC, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet 2016; 388:983.
  23. Kortram K, Ijzermans JN, Dor FJ. Perioperative Events and Complications in Minimally Invasive Live Donor Nephrectomy: A Systematic Review and Meta-Analysis. Transplantation 2016; 100:2264.
  24. Sawinski D, Trofe-Clark J, Leas B, et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant 2016; 16:2117.
  25. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375:323.
Topic 8352 Version 6886.0

Topic Outline

GRAPHICS

RELATED TOPICS

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.